



**meetings
in a box**

ROAD TO



WCLC 2025

A cura di Marco Tagliamento, Genova



ACCADEMIA NAZIONALE DI MEDICINA

Presidential Symposium

NSCLC METASTATICO

- **FLAURA2:** First-Line Osimertinib + Chemotherapy Versus Osimertinib Monotherapy in EGFRm Advanced NSCLC. Final Overall Survival. (P02.04)
- **HARMONI:** Ivonescimab vs Placebo Plus Chemo in Patients with EGFR+ NSCLC Progressed with 3rd gen EGFR-TKI. (P02.08)

NSCLC LOCALIZZATO/LOC. AVANZATO

- Phase 3 Trial of Crizotinib vs Observation for Surgically Resected Early-Stage ALK+ NSCLC. (P02.12)
- **NADIM ADJUVANT:** Adjuvant Chemotherapy (CT) vs CT-immunotherapy for R0 Stage IB-IIIa NSCLC Patients. (P03.07)

Oral Presentations

NSCLC METASTATICO

- **ZEAL-1L**: A Randomized Phase 3 Study of Niraparib Plus Pembrolizumab as Maintenance Therapy for Advanced/Metastatic NSCLC. (OA05.02)
- **IFCT-1805 Elderly**: First-Line Atezolizumab Plus Chemotherapy in Elderly Patients With Advanced NSCLC. (OA05.04)

NSCLC LOCALIZZATO/LOC. AVANZATO

- **SKYSCRAPER-05**: Phase II Study of Perioperative Tiragolumab + Atezolizumab ± Chemotherapy in Locally Advanced Resectable NSCLC. (OA02.01)
- **NeoADAURA**: Neoadjuvant Osimertinib ± Chemotherapy in Resectable EGFRm NSCLC. Molecular Residual Disease (MRD) Analysis. (OA02.02)

Mini Oral Presentations

NSCLC METASTATICO

- GFH375 in Advanced Non-small Cell Lung Cancer Patients with KRAS G12D Mutation. (**MA02.07**)
- **LiBRA Study (GOIRC-03-2020)**: Liquid Biopsy in BRAF V600E NSCLC Treated With Dabrafenib Plus Trametinib. (**MA02.05**)
- **SAVANNAH**: Biomarker Concordance and Acquired Resistance in Patients with EGFRm MET-OverExp and / or Amp NSCLC. (**MA03.03**)

NSCLC LOCALIZZATO/LOC. AVANZATO

- **Nautika1**: Clinical Outcomes and Pathologic Regression With Neoadjuvant Alectinib in Resectable Stage IB-IIIB ALK + NSCLC. (**MA04.02**)
- Neoadjuvant Pembrolizumab: Multi-Omics Characterization of the Tumoral Immune Response Reveals Distinct Mechanisms of Action. (**MA04.06**)